Why did biochemical control not translate into a survival increase after brachy boost therapy?

The first randomized clinical trial to prove that brachy boost radiotherapy had better oncological outcomes among high-risk patients was the one published by Sathya et al. in 2005. … READ MORE …

Brachy boost therapy should be reserved for unfavorable risk patients

The ASCENDE-RT trial showed that oncological outcomes were improved among both intermediate-risk and high-risk men who were treated with external beam radiation (EBRT) and a brachytherapy boost (LDR-BT) to the prostate and adjuvant androgen deprivation therapy (ADT) (see this link). … READ MORE …

Brachy boost: the gold standard for progression-free survival of high-risk prostate cancer

Several randomized clinical trials have established the superior oncological outcomes of the combination of external beam radiotherapy with a high-dose-rate brachytherapy boost (see this link). … READ MORE …

For very high-risk patients, EBRT + BT is superior to surgery or EBRT only (redux)

In August last year, Kishan et al. showed a preliminary analysis of oncological outcomes among patients diagnosed with Gleason score 9 and 10 and treated with brachy boost therapy (EBRT + BT), external beam radiation therapy alone (EBRT), or surgery (see this link). … READ MORE …

For very high-risk patients, EBRT + BT is superior to surgery or EBRT only

A retrospective analysis of oncological outcomes among modern-era patients with a Gleason score of 9 or 10 demonstrates a clear advantage to a combination of external beam radiation therapy (EBRT) with a brachytherapy (BT) boost to the prostate and short–term androgen deprivation therapy (ADT). … READ MORE …

SBRT boost radiation therapy in intermediate- and high-risk prostate cancer

Recently we have seen evidence of improved cancer control in high-risk patients treated with external beam radiotherapy with a brachytherapy boost to the prostate. This has been demonstrated with both HDR brachytherapy boost and with LDR brachytherapy boost. … READ MORE …

High-dose EBRT, very high-dose EBRT, or brachy boost therapy – which is best for intermediate- and high-risk patients?

At last week’s Genitourinary Cancers Symposium, Amini et al. presented the results of a data analysis that addresses the question of which kind of high-dose radiation therapy has the best cancer control rates … READ MORE …

Brachytherapy boost may lower mortality rate in high-risk patients

The ASCENDE-RT randomized clinical trial demonstrated that the combination of external beam radiation therapy with a brachytherapy boost (EBRT + BT) significantly reduced biochemical progression-free survival. … READ MORE …

“Dose painting” — a new type of radiation therapy for prostate cancer?

Two technologies have been brought together to allow for a new kind of radiation treatment known as simultaneous integrated boost (SIB) or, more informally, “dose painting.” … READ MORE …

Early data from the ASCENDE-RT trial misleadingly presented

News reports (and apparently a media release) have been suggesting that ‘A prostate cancer treatment using permanently implanted radioactive “seeds” doubles rates of 5-year tumor-free survival compared with conventional high-dose radiotherapy.’ Unfortunately, these reports are somewhat — or perhaps very — misleading. … READ MORE …

EBRT + LDRBT boost provides superior cancer control compared to EBRT alone

Numerous retrospective analyses have suggested that the combination of external beam radiation therapy (EBRT) with a low-dose-rate brachytherapy (LDRBT) boost is highly effective in controlling prostate cancer in unfavorable-risk patients. … READ MORE …

A long way from actual clinical applicability, but interesting anyway …

There was an intriguing paper in the November 2013 issue of the journal Prostate suggesting that intermittent dosing with testosterone in between doses of androgen deprivation therapies may actually help men in the early stages of castration resistance to respond better to treatment over time. … READ MORE …

Outcomes following EBRT and an SBRT “boost” for localized prostate cancer

New data from the radiotherapy group at the University of Califronia, San Francisco suggests that stereotactic body radiation (SBRT) can be used to deliver a “boost” of focused radiation after external beam radiation therapy (EBRT). High dose rate (HDR) brachytherapy has also been used in this way in the past. … READ MORE …